



Prescriber Follow-up of Pharmacist Clinical Interventions in an Australian Teaching Hospital

Jennifer Ly¹, Christine Coorey², Jonathan Penm¹, Carl Schneider¹

1. The University of Sydney School of Pharmacy, NSW, Australia

2. Department of Pharmacy, Westmead Hospital, NSW, Australia

Aim: To describe the type of clinical interventions reported by clinical pharmacists and identify factors that predict prescriber follow-up of clinical interventions.

Introduction

- Clinical pharmacists review medication orders and document **clinical interventions** as part of routine practice.
- This allows communication of suggested changes to medication therapy, optimises medication use and enhances **patient safety** and the quality of the **patient's care**.
- We sought to **quantify** the proportion of **follow-up** performed of pharmacist-identified **clinical interventions** by prescribers.

Methods

- **Retrospective review** of clinical interventions reported on NIMC and discharge prescriptions by pharmacists at a large teaching hospital in New South Wales, Australia. 
- Study period: the first weeks of February, May, August and November of 2017. These months were chosen to account for **prescriber maturity** and **workload** at different times of the year.
- Follow-up: *“any action documented on the medical records by a prescriber that addressed the pharmacist-identified clinical intervention”*.
- Descriptive analyses to characterise the **type** of **clinical interventions** and **quantify follow-up** activity.
- Binary logistic multivariate regression to **identify predictors** of follow-up activity.

Results

- A total of 396 clinical interventions were reported.
- Clinical interventions were reported most commonly for **anti-infectives**, **cardiovascular** and **respiratory** drugs. 
- **Dose selection** with unclear or incorrect instructions was the most common type of clinical intervention.¹

- Over **two-thirds (n=262, 66%)** of clinical interventions were followed up by prescribers. 
- Factors that predicted prescriber follow-up activity:
 - **Polypharmacy**, OR 2.3 (1.3-4.1)
 - Clinical interventions documented on **discharge prescriptions**, OR 6.4 (2.0-21.0)
 - Clinical interventions documented in **August**, OR 2.3 (1.1-5.2)
 - Patients admitted under a **medical speciality** (vs surgical), OR 2.1 (1.1-4.0)

Table 1: Follow-up rates of clinical interventions

Clinical intervention ¹	Follow-up, n (%)	Total
Dose selection	138 (64.7)	215
Drug use process	25 (49.0)	51
Logistics	36 (72.0)	50
Drug selection	39 (81.3)	48
Drug form	16 (66.7)	24
Other	7 (87.5)	8

Discussion

- Follow-up of clinical interventions, particularly of **dose selection errors**, is necessary to minimise patient harm.
- Follow-up by prescribers was **less likely** when the **solution was clear** for pharmacists to amend the medication order themselves.
- Increased **winter workload** and pressures increased likelihood of prescriber follow-up in August.

Conclusion

- Follow-up of clinical interventions by prescribers appeared to be influenced by factors that pose a potential **risk of harm** to patients.

- **Standardisation** of clinical intervention prioritisation may improve prescriber follow-up.

Correspondence

jely2570@uni.sydney.edu.au

References

1. Basger BJ, Moles RJ, Chen TF. Development of an aggregated system for classifying causes of drug-related problems. Ann Pharmacother. 2015; [https:// 10.1177/1060028014568008](https://doi.org/10.1177/1060028014568008)